Maternal Visfatin Concentration in Normal Pregnancy

Overview

Journal J Perinat Med

Date 2009 Mar 17

PMID 19284295

Citations 28

Authors

Shali Mazaki-Tovi

Roberto Romero

Juan Pedro Kusanovic

Edi Vaisbuch

Offer Erez

Nandor Gabor Than

Tinnakorn Chaiworapongsa

Chia-Ling Nhan-Chang

Percy Pacora

Francesca Gotsch

Lami Yeo

Sun Kwon Kim

Samuel S Edwin

Sonia S Hassan

Pooja Mittal

Affiliations

Soon will be listed here.

Abstract

Objective: Adipose tissue has now emerged as a powerful endocrine organ via the production of adipokines. Visfatin, a novel adipokine with diabetogenic and immuno-modulatory properties has been implicated in the pathophysiology of insulin resistance in patients with obesity and Type-2 diabetes mellitus. The aim of this study was to determine whether there are changes in the maternal plasma concentration of visfatin with advancing gestation and as a function of maternal weight.

Study Design: In this cross-sectional study, maternal plasma concentrations of visfatin were determined in normal weight and overweight/obese pregnant women in the following gestational age groups: 1) 11-14 weeks (n=52); 2) 19-26 weeks (n=68); 3) 27-34 weeks (n=93); and 4) >37 weeks (n=60). Visfatin concentrations were determined by ELISA. Non parametric statistics were used for analysis.

Results: 1) The median maternal plasma visfatin concentration was higher in pregnant women between 19-26 weeks of gestation than that of those between 11-14 weeks of gestation (P<0.01) and those between 27-34 weeks of gestation (P<0.01); 2) among normal weight pregnant women, the median plasma visfatin concentrations of women between 19-26 weeks of gestation was higher than that of those between 11-14 weeks (P<0.01) and those between 27-34 weeks (P<0.01); and 3) among overweight/obese patients, the median maternal visfatin concentration was similar between the different gestational age groups.

Conclusion: The median maternal plasma concentration of visfatin peaks between 19-26 and has a nadir between 27-34 weeks of gestation. Normal and overweight/obese pregnant women differed in the pattern of changes in circulating visfatin concentrations as a function of gestational age.

Citing Articles

Longitudinal Study of Plasma Visfatin/Nicotinamide Phosphoribosyltransferase (NAMPT) Levels in Healthy Pregnant Women.

Nunes P, Cavalli R, Belo V, Sandrim V, Luizon M Reprod Sci. 2023; 30(10):2893-2895.

PMID: 37118060 DOI: 10.1007/s43032-023-01246-4.

Deep Insight of the Pathophysiology of Gestational Diabetes Mellitus.

Sharma A, Singh S, Singh H, Mahajan D, Kolli P, Mandadapu G Cells. 2022; 11(17).

PMID: 36078079 PMC: 9455072. DOI: 10.3390/cells11172672.

Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus.

Ruszala M, Niebrzydowska M, Pilszyk A, Kimber-Trojnar Z, Trojnar M, Leszczynska-Gorzelak B Int J Mol Sci. 2021; 22(21).

PMID: 34769010 PMC: 8584125. DOI: 10.3390/ijms222111578.

GDM-complicated pregnancies: focus on adipokines.

Mallardo M, Ferraro S, Daniele A, Nigro E Mol Biol Rep. 2021; 48(12):8171-8180.

PMID: 34652617 PMC: 8604848. DOI: 10.1007/s11033-021-06785-0.

Dietary Blueberry and Soluble Fiber Improve Serum Antioxidant and Adipokine Biomarkers and Lipid Peroxidation in Pregnant Women with Obesity and at Risk for Gestational Diabetes.

Basu A, Crew J, Ebersole J, Kinney J, Salazar A, Planinic P Antioxidants (Basel). 2021; 10(8).

PMID: 34439566 PMC: 8389321. DOI: 10.3390/antiox10081318.

References

Xie H, Tang S, Luo X, Huang J, Cui R, Yuan L . Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 2007; 80(3):201-10. DOI: 10.1007/s00223-006-0155-7. View

Lopez-Bermejo A, Fernandez-Real J, Garrido E, Rovira R, Brichs R, Genaro P . Maternal soluble tumour necrosis factor receptor type 2 (sTNFR2) and adiponectin are both related to blood pressure during gestation and infant's birthweight. Clin Endocrinol (Oxf). 2004; 61(5):544-52. DOI: 10.1111/j.1365-2265.2004.02120.x. View

Tsai P, Yu C, Hsu S, Lee Y, Huang I, Ho S . Maternal plasma adiponectin concentrations at 24 to 31 weeks of gestation: negative association with gestational diabetes mellitus. Nutrition. 2005; 21(11-12):1095-9. DOI: 10.1016/j.nut.2005.03.008. View

Beck P . Progestin enhancement of the plasma insulin response to glucose in Rhesus monkeys. Diabetes. 1969; 18(3):146-52. DOI: 10.2337/diab.18.3.146. View

Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R . Serum visfatin increases with progressive beta-cell deterioration. Diabetes. 2006; 55(10):2871-5. DOI: 10.2337/db06-0259. View

Qiu C, Sorensen T, Luthy D, Williams M . A prospective study of maternal serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol. 2004; 18(5):377-84. DOI: 10.1111/j.1365-3016.2004.00578.x. View

Lu D, Yang X, Wu Y, Wang H, Huang H, Dong M . Serum adiponectin, leptin and soluble leptin receptor in pre-eclampsia. Int J Gynaecol Obstet. 2006; 95(2):121-6. DOI: 10.1016/j.ijgo.2006.06.015. View

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83. DOI: 10.1006/bbrc.1999.0255. View

Catalano P, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S . Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. Diabetologia. 2006; 49(7):1677-85. DOI: 10.1007/s00125-006-0264-x. View

10.

McLachlan K, ONeal D, Jenkins A, Alford F . Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev. 2005; 22(2):131-8. DOI: 10.1002/dmrr.591. View

11.

Teppa R, Ness R, Crombleholme W, Roberts J . Free leptin is increased in normal pregnancy and further increased in preeclampsia. Metabolism. 2000; 49(8):1043-8. DOI: 10.1053/meta.2000.7707. View

12.

Berg A, Scherer P . Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96(9):939-49. DOI: 10.1161/01.RES.0000163635.62927.34. View

13.

Coppack S . Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001; 60(3):349-56. DOI: 10.1079/pns2001110. View

14.

Nien J, Mazaki-Tovi S, Romero R, Erez O, Kusanovic J, Gotsch F . Adiponectin in severe preeclampsia. J Perinat Med. 2007; 35(6):503-12. PMC: 2572000. DOI: 10.1515/JPM.2007.121. View

15.

Tan B, Chen J, Digby J, Keay S, Kennedy C, Randeva H . Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab. 2006; 91(12):5022-8. DOI: 10.1210/jc.2006-0936. View

16.

Berg A, Combs T, Scherer P . ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002; 13(2):84-9. DOI: 10.1016/s1043-2760(01)00524-0. View

17.

Lonnqvist F, Arner P, Nordfors L, Schalling M . Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med. 1995; 1(9):950-3. DOI: 10.1038/nm0995-950. View

18.

Gabbe S . Management of diabetes mellitus in pregnancy. Am J Obstet Gynecol. 1985; 153(8):824-8. DOI: 10.1016/0002-9378(85)90683-0. View

19.

Montague C, Prins J, Sanders L, Zhang J, Sewter C, Digby J . Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes. 1998; 47(9):1384-91. DOI: 10.2337/diabetes.47.9.1384. View

20.

Chan T, Chen Y, Lee C, Chou F, Wu L, Jong S . Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig. 2006; 13(5):364-7. DOI: 10.1016/j.jsgi.2006.04.007. View